Drugs that contain Pexidartinib Hydrochloride

1. List of Turalio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(10 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity
Apr, 2028

(5 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(10 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 2, 2024
ODE* (ODE*) Aug 2, 2026
Orphan Drug Exclusivity (ODE) Aug 2, 2026

NCE-1 date: 2023-08-03

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage

TURALIO family patents

39

United States

10

Japan

7

China

7

European Union

6

Korea, Republic of

5

Brazil

5

Canada

5

Australia

4

Singapore

4

Spain

4

Taiwan, Province of China

3

Hong Kong

3

South Africa

3

Israel

2

Portugal

2

Malaysia

2

Russia

2

Colombia

2

New Zealand

2

Mexico

2

Slovenia

2

Hungary

2

Denmark

1

El Salvador

1

Uruguay

1

Guatemala

1

Croatia

1

Costa Rica

1

Norway

1

Philippines

1

Argentina

1

Peru

1

EA

1

Nicaragua

1

Lithuania

1

Cyprus

1

Ukraine

1

Poland

1

Chile

1

RS

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic